OR WAIT null SECS
Sabinsa says the agency found a minor, now-corrected issue at one of the facilities.
FDA has inspected five of Sabinsa Corp.’s SAMI Labs manufacturing facilities in India, finding minor issue with just one of those facilities, as Sabinsa explains:
“The issue involved a polyliner becoming tangled in the conveyer belts leading to the extraction chamber; corrective action included changing to HDPE bags without lining and improving hopper and mesh at the point of feeding raw material into the extraction equipment.”
The inspected facilities were located in Kunigal, Nelamangala, and Dobaspet (Karnataka), and Genome Valley, Hyderabad.